These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28556449)

  • 1. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
    McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
    Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity.
    Shoemaker A; Proietto J; Abuzzahab MJ; Markovic T; Malloy J; Kim DD
    Diabetes Obes Metab; 2017 Aug; 19(8):1165-1170. PubMed ID: 28261955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
    Proietto J; Malloy J; Zhuang D; Arya M; Cohen ND; de Looze FJ; Gilfillan C; Griffin P; Hall S; Nathow T; Oldfield GS; O'Neal DN; Roberts A; Stuckey BGA; Yue D; Taylor K; Kim D
    Diabetologia; 2018 Sep; 61(9):1918-1922. PubMed ID: 29992370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial.
    Kim DD; Krishnarajah J; Lillioja S; de Looze F; Marjason J; Proietto J; Shakib S; Stuckey BGA; Vath JE; Hughes TE
    Diabetes Obes Metab; 2015 Jun; 17(6):566-572. PubMed ID: 25732625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women.
    Hughes TE; Kim DD; Marjason J; Proietto J; Whitehead JP; Vath JE
    Obesity (Silver Spring); 2013 Sep; 21(9):1782-8. PubMed ID: 23512440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061.
    Burkey BF; Hoglen NC; Inskeep P; Wyman M; Hughes TE; Vath JE
    J Pharmacol Exp Ther; 2018 May; 365(2):301-313. PubMed ID: 29491038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
    Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
    Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity.
    Elfers CT; Roth CL
    Endocrinology; 2017 Jan; 158(1):41-55. PubMed ID: 27849360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
    Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
    J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
    Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
    Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
    PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.
    Hollander E; Levine KG; Ferretti CJ; Freeman K; Doernberg E; Desilva N; Taylor BP
    J Psychiatr Res; 2021 May; 137():643-651. PubMed ID: 33190843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
    Kimonis V; Surampalli A; Wencel M; Gold JA; Cowen NM
    PLoS One; 2019; 14(9):e0221615. PubMed ID: 31545799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
    Diene G; Angulo M; Hale PM; Jepsen CH; Hofman PL; Hokken-Koelega A; Ramesh C; Turan S; Tauber M
    J Clin Endocrinol Metab; 2022 Dec; 108(1):4-12. PubMed ID: 36181471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
    Dykens EM; Miller J; Angulo M; Roof E; Reidy M; Hatoum HT; Willey R; Bolton G; Korner P
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
    Miller JL; Gevers E; Bridges N; Yanovski JA; Salehi P; Obrynba KS; Felner EI; Bird LM; Shoemaker AH; Angulo M; Butler MG; Stevenson D; Abuzzahab J; Barrett T; Lah M; Littlejohn E; Mathew V; Cowen NM; Bhatnagar A;
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1676-1685. PubMed ID: 36639249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
    Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
    Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspergillus, angiogenesis, and obesity: the story behind beloranib.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Mar; 53(3):13-6. PubMed ID: 25751824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.